Clinical trials · Missouri
Alzheimer’s disease clinical trials in Missouri
We’re tracking 36 recruiting alzheimer’s disease studies with a site in Missouri — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Missouri
- NCT06416072Enrolling by invitation
Blood marker study for people not eligible for Alzheimer's prevention trials
This study looks at blood markers in people who were part of an early Alzheimer's prevention study but did not qualify for it because their amyloid levels were too low. It aims to understand brain changes and possibly find ways to detect Alzheimer's even earlier.
St Louis, MissouriAges 55–80 - NCT06847321RecruitingPhase 2
Testing LHP588 for Alzheimer's linked to a mouth bacteria
This trial tests a new medication, LHP588, for people with Alzheimer's who also have a common mouth bacteria called P. gingivalis. The goal is to see if targeting this bacteria can help slow down memory loss.
Chesterfield, MissouriAges 55–80 - NCT05010603Recruiting
Studies families to understand late-onset Alzheimer’s
This study focuses on people with late-onset Alzheimer’s (and some similar memory diseases) and uses a close family “informant” to share what they’ve noticed. It may help researchers learn more about these conditions and how they progress in families.
St Louis, MissouriAges 55 years+ - NCT05462106RecruitingPhase 1/Phase 2
ACI-24.060 study for early Alzheimer’s in adults and Down syndrome
This Phase 1/2 study tests an Alzheimer’s treatment called ACI-24.060 to see if it affects the disease in people with early Alzheimer’s changes. It includes two groups: older adults with early symptoms and people with Down syndrome who also show Alzheimer’s-related changes on brain scans.
St Louis, MissouriAges 35–85 - NCT06372821RecruitingPhase 1
Study of NIO752 for Alzheimer's disease
This study tests an experimental drug called NIO752 to see if it can reduce the production of tau protein, which is linked to Alzheimer's disease. Researchers will measure how the drug affects tau in your body using a special technique called SILK.
St Louis, MissouriAges 21–80 - NCT05552157RecruitingPhase 2/Phase 3
Study of treatments for early onset Alzheimer's caused by genetic mutations
This trial tests potential treatments for people who are at risk for or have early onset Alzheimer's disease due to a specific genetic mutation. It aims to find treatments that could slow or prevent symptoms.
St Louis, MissouriAges 18 years+ - NCT06647498RecruitingPhase 2/Phase 3
Study of a treatment for early-onset Alzheimer's caused by a gene change
This study tests a potential disease-modifying treatment for people who have a specific gene mutation that causes early-onset Alzheimer's disease. The goal is to see if the treatment can delay or prevent symptoms.
St Louis, MissouriAges 18 years+ - NCT07169578RecruitingPhase 3
A study of trontinemab for early Alzheimer's disease
This trial tests a new drug called trontinemab for people with early Alzheimer's disease. The goal is to see if it can help slow down memory and thinking problems.
St Louis, MissouriAges 50–90 - NCT02414347Recruiting
Tau PET scan study for Alzheimer’s disease
This study uses a PET brain scan with a small injected tracer to look for “tau” protein changes linked to Alzheimer’s disease. It may help researchers better understand how tau appears in people who are cognitively normal or have mild dementia.
St Louis, MissouriAges 18 years+ - NCT07177352RecruitingPhase 3
Screening for Roche Alzheimer's studies
This is a screening study to find people who might be eligible for other Alzheimer's drug studies run by the same company. It helps match you to a treatment trial if you qualify.
St Louis, MissouriAges 50–90 - NCT07011745RecruitingPhase 3
Study of KarXT for Alzheimer's Agitation
This study tests a new drug combination (KarXT + KarX-EC) to see if it can safely reduce agitation in people with Alzheimer's disease. It may help if you or your loved one has bothersome agitation that affects daily life.
Ozark, MissouriAges 55–90 - NCT07633470RecruitingPhase 4
Zunveyl for Alzheimer's disease symptoms and caregiver support
This study tests a medication called Zunveyl to see if it helps reduce behavioral and neuropsychiatric symptoms in people with mild-to-moderate Alzheimer's disease, and whether it reduces stress on family caregivers. You would need a confirmed Alzheimer's diagnosis supported by a blood test, and a dedicated caregiver who can attend visits and report on your symptoms.
St Louis, MissouriAges 50 years+ - NCT04629547RecruitingPhase 2
Sleep study to help prevent Alzheimer’s disease
This trial tests whether treating sleep issues and measuring sleep can help lower the risk of Alzheimer’s disease before it starts. It focuses on older adults with no dementia signs yet.
St Louis, MissouriAges 65 years+ - NCT06274528RecruitingPhase 2
DORA and lemborexant in Alzheimer's biomarkers study
This study is testing whether a sleep medication called lemborexant can improve sleep and reduce Alzheimer's-related proteins in healthy older adults with no memory problems. It could help find new ways to delay or prevent Alzheimer's disease.
St Louis, MissouriAges 65 years+ - NCT07094516RecruitingPhase 2
Testing VHB937 for early Alzheimer's disease
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
Bolivar, MissouriAges 50–85 - NCT06159673RecruitingPhase 2/Phase 3
ACP-204 for Alzheimer's with psychosis
This study tests a new medicine called ACP-204 for people with Alzheimer's disease who also have psychosis (like seeing or hearing things that aren't real). It aims to see if the drug can help reduce these symptoms safely.
St Louis, MissouriAges 55–95 - NCT06439992Recruiting
New PET scan tracer to detect Alzheimer's in the brain
This study tests a new PET imaging tracer called Fluselenamyl to see how well it shows amyloid plaques (a protein linked to Alzheimer's) in the brain. It may help improve early diagnosis for people with Alzheimer's or support research in healthy volunteers.
St Louis, MissouriAges 18 years+ - NCT06585787RecruitingPhase 3
Testing KarXT for psychosis in Alzheimer’s disease
This study tests an investigational medication (KarXT) for treating psychosis—hallucinations or delusions—in people with Alzheimer’s disease. It aims to see if the drug can reduce these symptoms safely and effectively.
St Louis, MissouriAges 55–90 - NCT07033494RecruitingPhase 2
Study of MK-2214 for early Alzheimer's disease
This trial tests an experimental medicine called MK-2214 for people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow memory and thinking problems.
Chesterfield, MissouriAges 50–85 - NCT07284472RecruitingPhase 2/Phase 3
Testing drugs for agitation in Alzheimer's disease
This trial tests two new drugs (EXV-802 and EXV-801) to see if they can safely reduce moderate to severe agitation in people with Alzheimer's dementia. If you or a loved one has Alzheimer's and has been experiencing significant agitation for at least two weeks, this study may be an option.
Chesterfield, MissouriAges 55–90 - NCT05617014Enrolling by invitation
ADNI4 study for early Alzheimer’s with brain imaging tests
This study enrolls people with no memory impairment, mild memory problems, or mild Alzheimer’s dementia to test how brain scans and cognitive tests relate to Alzheimer’s disease. It may help by contributing to better early diagnosis and by letting you see whether you fit into the study’s imaging and blood-test pathway.
St Louis, MissouriAges 55–90 - NCT05980949RecruitingPhase 3
Long-term safety study of KarXT for Alzheimer's psychosis
This trial tests the long-term safety of an investigational drug called KarXT for people with psychosis caused by Alzheimer's disease. It is for those who have already completed a previous KarXT study and want to continue treatment.
St Louis, MissouriAges 55–90 - NCT06129838Recruiting
Inflammation in Alzheimer's disease using a brain scan
This study uses a special PET scan to look for inflammation in the brains of people with Alzheimer's or related dementias. It may help researchers understand how inflammation affects memory and thinking problems.
St Louis, MissouriAges 50 years+ - NCT05077579Recruiting
Alzheimer’s scan study for people with higher body weight
This study uses brain scans (MRI and two special PET scans) to see how Alzheimer’s-related changes show up in people who are overweight or obese, with different blood-sugar and insulin patterns. It may help researchers understand whether body weight and metabolism affect early Alzheimer’s markers in the brain.
St Louis, MissouriAges 40–60
Alzheimer’s disease trials by city in Missouri
Where these studies are running in Missouri
Institutions with a site for the recruiting alzheimer’s disease studies listed above.
- Washington University in St. Louis · 14 studies
- Tekton Research · 3 studies
- Clinical Research Professionals · 2 studies
- Citizens Memorial Hospital
- Galen Research
- Joanne Norton
- Local Institution - 1255
- Local Institution - 2603
What taking part in a alzheimer’s disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Alzheimer’s disease trials in other states
Common questions
- Are there alzheimer’s disease clinical trials in Missouri?
- Yes. We're currently tracking 36 recruiting alzheimer’s disease studies with a site in Missouri, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a alzheimer’s disease study in Missouri?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Missouri to take part?
- Not necessarily. These studies have a site in Missouri, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a alzheimer’s disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New alzheimer’s disease studies open in Missouri regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.